PTEN (gene)
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
|
WikiDoc Resources for PTEN (gene) | |
|
Articles | |
|---|---|
|
Most recent articles on PTEN (gene) Most cited articles on PTEN (gene) | |
|
Media | |
|
Powerpoint slides on PTEN (gene) | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on PTEN (gene) at Clinical Trials.gov Clinical Trials on PTEN (gene) at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on PTEN (gene)
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on PTEN (gene) Discussion groups on PTEN (gene) Patient Handouts on PTEN (gene) Directions to Hospitals Treating PTEN (gene) Risk calculators and risk factors for PTEN (gene)
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for PTEN (gene) | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
PTEN (Phosphatase and Tensin homolog) gene is a human gene that acts as a tumor suppressor gene, which means that the protein encoded by this gene helps regulate the cycle of cell division by keeping cells from growing and dividing too rapidly or in an uncontrolled way. Mutations of this gene cause multiple advanced cancers.
The corresponding PTEN protein is found in almost all tissues in the body. The PTEN protein modifies lipids (fats) in cells by removing phosphate groups (clusters of one phosphorous and three oxygen atoms), making the PTEN protein a type of enzyme called a phosphatase. More specifically it is a phosphodiesterase and an inhibitor of the phospho-AKT pathway by removing the 3' phosphate group of phosphatidylinositol (3,4,5)-trisphosphate (PtdIns (3,4,5)P3).
The structure of PTEN (solved by X-ray crystallography) reveals that it consists of a phosphatase domain, and a C2 domain: the phosphatase domain contains the active site which carries out the enzymatic function of the protein, whilst the C2 domain allows PTEN to bind to the phospholipid membrane so it is able to de-phosphorylate (PtdIns (3,4,5)P3)
When the PTEN enzyme is functioning properly, it acts as part of a chemical pathway that signals cells to stop dividing and causes cells to undergo programmed cell death (apoptosis) when necessary. These functions prevent uncontrolled cell growth that can lead to the formation of tumors. There is also evidence that the protein made by the PTEN gene may play a role in cell movement (migration) and sticking (adhesion) of cells to surrounding tissues.
PTEN is one of the most commonly lost tumour suppressors in human cancer. During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, prostate cancer, and reduced expression is found in many other tumor types such as lung and breast cancer.
Related conditions
PTEN mutation also causes a variety of inherited predispositions to cancer.
Cowden syndrome: Researchers have found more than 70 mutations in the PTEN gene in people with Cowden syndrome. These mutations can be changes in a small number of base pairs or, in some cases, deletions of a large number of base pairs. Most of these mutations cause the PTEN gene to make a protein that does not function properly or does not work at all. The defective protein is unable to stop cell division or signal abnormal cells to die, which can lead to tumor growth, particularly in the breast, thyroid or uterus.
Other disorders: Mutations in the PTEN gene cause several other disorders that, like Cowden syndrome, are characterized by the development of noncancerous tumors called hamartomas. These disorders include Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndrome. Together, the disorders caused by PTEN mutations are called PTEN hamartoma tumor syndromes, or PHTS. Mutations responsible for these syndromes cause the resulting protein to be nonfunctional or absent. The defective protein allows the cell to divide in an uncontrolled way and prevents damaged cells from dying, which can lead to the growth of tumors.
Further Reading
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997). "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.". Science 275 (5308): 1943-1947. PMID 9072974.
- Simpson L, Parsons R (2001). "PTEN: life as a tumor suppressor". Exp Cell Res 264 (1): 29-41. PMID 11237521.
- Chu EC, Tarnawski AS (2004). "PTEN regulatory functions in tumor suppression and cell biology". Med Sci Monit 10 (10): RA235-41. PMID 15448614.
- Eng C (2003). "PTEN: one gene, many syndromes". Hum Mutat 22 (3): 183-98. PMID 12938083.
- Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, Miyazaki J, Suda T, Itoh H, Nakao K, Mak TW, Nakano T, Suzuki A (2005). "The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis". Genes Dev 19 (17): 2054–65. PMID 16107612.
- Leslie NR, Downes CP (2004). "PTEN function: how normal cells control it and tumour cells lose it". Biochem J 382 (Pt 1): 1–11. PMID 15193142.
- Pilarski R, Eng C (2004). "Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome". J Med Genet 41 (5): 323-6. PMID 15121767.
- Sansal I, Sellers WR (2004). "The biology and clinical relevance of the PTEN tumor suppressor pathway". J Clin Oncol 22 (14): 2954–63. PMID 15254063.
- Waite KA, Eng C (2002). "Protean PTEN: form and function". Am J Hum Genet 70 (4): 829-44. PMID 11875759.
- Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, Matloff E, Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C (2003). "Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway". Am J Hum Genet 73 (2): 404-11. PMID 12844284.
External links
- The PTEN Protein
- GeneCard
- UMich Orientation of Proteins in Membranes protein/pdbid-1d5r
- MeSH PTEN+Protein
Hydrolase: esterases (EC 3.1) | |
|---|---|
| 3.1.1: Carboxylic ester hydrolases | Cholinesterase - Pectinesterase - 6-phosphogluconolactonase - PAF acetylhydrolase
Lipase (Gastric/Lingual, Pancreatic, Lysosomal, Hormone-sensitive, Endothelial, Hepatic, Lipoprotein, Monoacylglycerol, Diacylglycerol) Phospholipase (A1, A2, B) |
| 3.1.2: Thioesterase | Palmitoyl thioesterase - Ubiquitin carboxy-terminal hydrolase L1 |
| 3.1.3: Phosphatase | Alkaline phosphatase - Acid phosphatase (Prostatic)/Tartrate resistant acid phosphatase/Purple acid phosphatases - Nucleotidase - Glucose 6-phosphatase - Fructose 1,6-bisphosphatase - Calcineurin - Phosphoprotein phosphatase (PP2A) - OCRL - Pyruvate dehydrogenase phosphatase - Fructose 2,6-bisphosphatase - Protein tyrosine phosphatase - PTEN |
| 3.1.4: Phosphodiesterase | Autotaxin - Phospholipase (C, D) - Sphingomyelin phosphodiesterase - PDE1 - PDE2 - PDE3 - PDE5 |
| 3.1.6: Sulfatase | Arylsulfatase B - Steroid sulfatase - Galactosamine-6 sulfatase - Arylsulfatase A - Iduronate-2-sulfatase - N-acetylglucosamine-6-sulfatase |
| other | Nuclease |
Tumor suppressor genes/proteins |
|---|
| APC - BRCA1 - BRCA2 - CHEK2 - Neurofibromin 1 - Maspin - Neurofibromin 2/Merlin - p14arf - p16 - p21 - p27 - p53 - p57 - p73 - pRb - PTEN - SDHB - SDHD - VHL |
WikiDoc Research Resources for PTEN (gene) | |
|---|---|
| Articles on PTEN (gene) | Most recent articles on PTEN (gene) • Most cited articles on PTEN (gene) • Review articles on PTEN (gene) • Articles on PTEN (gene) in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on PTEN (gene) | Powerpoint slides on PTEN (gene) • Images of PTEN (gene) • Photos of PTEN (gene) • Podcasts & MP3s on PTEN (gene) • Videos on PTEN (gene) |
| Evidence Based Medicine Regarding PTEN (gene) | Cochrane Collaboration on PTEN (gene) • Bandolier on PTEN (gene) • TRIP on PTEN (gene) |
| Cost Effectiveness of PTEN (gene) | Cost Effectiveness of PTEN (gene) |
| Clinical Trials Involving PTEN (gene) | Ongoing Trials on PTEN (gene) at Clinical Trials.gov • Trial results on PTEN (gene) • Clinical Trials on PTEN (gene) at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding PTEN (gene) | US National Guidelines Clearinghouse on PTEN (gene) • NICE Guidance on PTEN (gene) • NHS PRODIGY Guidance • FDA on PTEN (gene) • CDC on PTEN (gene) |
| Textbook Information on PTEN (gene) | Books and Textbook Information on PTEN (gene) |
| Pharmacology Resources on PTEN (gene) | Dosing of PTEN (gene) • Drug interactions with PTEN (gene) • Side effects of PTEN (gene) • Allergic reactions to PTEN (gene) • Overdose information on PTEN (gene) • Carcinogenicity information on PTEN (gene) • PTEN (gene) in pregnancy • Pharmacokinetics of PTEN (gene) • |
| Genetics, Pharmacogenomics, and Proteinomics of PTEN (gene) | Genetics of PTEN (gene) • Pharmacogenomics of PTEN (gene) • Proteomics of PTEN (gene) |
| Newstories on PTEN (gene) | PTEN (gene) in the news • Be alerted to news on PTEN (gene) • News trends on PTEN (gene) |
| Commentary on PTEN (gene) | Blogs on PTEN (gene) |
| Patient Resources on PTEN (gene) | Patient resources on PTEN (gene) • Discussion groups on PTEN (gene) • Patient Handouts on PTEN (gene) • Directions to Hospitals Treating PTEN (gene) • Risk calculators and risk factors for PTEN (gene) |
| Healthcare Provider Resources on PTEN (gene) | Symptoms of PTEN (gene) • Causes & Risk Factors for PTEN (gene) • Diagnostic studies for PTEN (gene) • Treatment of PTEN (gene) |
| Continuing Medical Education (CME) Programs on PTEN (gene) | CME Programs on PTEN (gene) |
| International Resources on PTEN (gene) | PTEN (gene) en Espanol • PTEN (gene) en Francais |
| Business Resources on PTEN (gene) | PTEN (gene) in the Marketplace • Patents on PTEN (gene) |
| Informatics Resources on PTEN (gene) | List of terms related to PTEN (gene) |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

